Sensorion (ALSEN.PA, EURONEXT) earnings update 17 Mar 2026: key metrics to watch

Sensorion SA (ALSEN.PA) closed the trading day at €0.66 (EUR 0.664) after reporting results on 17 Mar 2026 that focus investors on cash runway, R&D progress and near-term catalysts. The ALSEN.PA stock reaction reflects a busy session with 5,674,624 shares traded versus an average of 2,691,412, and a intraday range of €0.66–€0.77. We examine the earnings detail, valuation metrics such as EPS -0.09 and PE -7.38, and what analysts and shareholders should watch next in the clinical-stage biotech’s pipeline and funding outlook.

Earnings snapshot: ALSEN.PA stock reaction and volume

Sensorion reported metrics that left the market cautious and traded with high volume; ALSEN.PA stock closed €0.66 down 2.92% on the day while volume hit 5,674,624, a relative volume of 2.11. The stock’s intraday high was €0.77 and low €0.66, showing swift profit-taking after the update.

Financials and valuation: EPS, cash and ratios

Sensorion shows EPS -0.09 and a trailing PE of -7.38, reflecting negative earnings but active R&D spending. Cash per share is €0.19 and book value per share is €0.19, while price to book sits at 3.61, indicating the market prices growth and pipeline value above current tangible equity.

Pipeline catalysts: programs that drive ALSEN.PA stock outlook

Key catalysts remain OTOF-GT for otoferlin deficiency, USHER-T1-GT for Usher syndrome Type 1 and SENS-401 for sudden sensorineural hearing loss, each linked to clinical milestones that can move ALSEN.PA stock materially once data readouts or regulatory steps arrive.

Technicals and trading: momentum, trend and liquidity

Momentum indicators show a short-term overbought condition with RSI 84.83 and strong trend signals (ADX 41.52), while the 50-day average €0.36 sits well below the current price, underlining recent strong price appreciation and higher volatility.

Meyka AI rates ALSEN.PA with a score out of 100 and model outlook

Meyka AI rates ALSEN.PA with a score of 66.37 / 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly target of €0.14, and that projection is model-based and not a guarantee.

Risks and near-term triggers affecting ALSEN.PA stock

Risks include clinical trial setbacks, higher-than-expected cash burn, and slow adoption of gene therapies; the current ratio 4.90 provides short-term liquidity cover but investors must watch funding statements and potential dilution ahead of pivotal milestones.

Final Thoughts

Key takeaways for the ALSEN.PA stock earnings spotlight: Sensorion finished the session at €0.66 (EUR 0.664) on 17 Mar 2026 with heavy trading and mixed signals — a robust volume surge of 5,674,624 shares but negative EPS -0.09 and an elevated price-to-book of 3.61. The company’s pipeline programs remain the primary upside trigger; successful clinical readouts or partnership advancements would likely re-rate the stock higher. Meyka AI’s forecast model projects €0.14 on a yearly horizon, implying an approximate -78.21% downside from EUR 0.664, though model outcomes vary by scenario and are not guarantees. For traders we suggest watching cash runway and upcoming readout dates; for longer-term investors, align position size to high volatility and potential dilution. Price targets we use for scenario planning are: conservative €0.30 (implied -54.82%), base €0.70 (implied +5.42%), bullish €1.20 (implied +80.72%). These targets reflect current valuation, pipeline risk and sector comparatives within healthcare on EURONEXT, and should be balanced with your risk tolerance. Meyka AI, an AI-powered market analysis platform, provides these data-driven views as informational only and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.